Company / PP&E (Net)
Enliven Therapeutics, Inc. PP&E (Net) History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$458.0K
FY2024
5-year range
$250.0K / $890.0K
FY2020-FY2024
Trend
-38.3%
vs FY2023
Sector context
#170 of 193
Health Care
What the data says
Enliven Therapeutics, Inc.'s pp&e (net) of $458,000 is lower than 88% of companies in the Health Care sector (FY2024). Declined from $890,000 to $458,000 over the past 2 years.
Based on SEC 10-K filings.
$458,000 in FY2024 with a 5-year CAGR of +0.7%.
Declined from $890,000 to $458,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +22.4%
- 5-Year CAGR
- +0.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 193This company $458.0K Sector average $777.6M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.7%, indicating consistent growth.
- In FY2024, pp&e (net) decreased 38.3% year-over-year.
- Ranks #170 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $458.0K | -38.3% |
| FY2023 | $742.0K | -16.6% |
| FY2022 | $890.0K | +256.0% |
| FY2021 | $250.0K | -28.4% |
| FY2020 | $349.0K | -21.0% |
| FY2019 | $442.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026